<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Case Rep Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Case Rep Psychiatry</journal-id><journal-id journal-id-type="publisher-id">CRIM.PSYCHIATRY</journal-id><journal-title-group><journal-title>Case Reports in Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">2090-682X</issn><issn pub-type="epub">2090-6838</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23533900</article-id><article-id pub-id-type="pmc">3603624</article-id><article-id pub-id-type="doi">10.1155/2013/617251</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Linezolid Is Associated with Serotonin Syndrome in a Patient Receiving Amitriptyline, and Fentanyl: A Case Report and Review of the Literature</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">0000-0002-4380-3036</contrib-id><name><surname>Samartzis</surname><given-names>Lampros</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Savvari</surname><given-names>Paraskevi</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kontogiannis</surname><given-names>Sofoklis</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">0000-0003-2199-3788</contrib-id><name><surname>Dimopoulos</surname><given-names>Stavros</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Psychiatry, Mental Health Services, Athalassa Psychiatric Hospital, 1452 Nicosia, Cyprus</aff><aff id="I2"><sup>2</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 80 Vas. Sofias Avenue, 11528 Athens, Greece</aff><author-notes><corresp id="cor1">*Stavros Dimopoulos: <email>stdimop@med.uoa.gr</email></corresp><fn fn-type="other"><p>Academic Editors: J. S. Brar and D. E. Dietrich</p></fn></author-notes><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>4</day><month>3</month><year>2013</year></pub-date><volume>2013</volume><elocation-id>617251</elocation-id><history><date date-type="received"><day>21</day><month>1</month><year>2013</year></date><date date-type="accepted"><day>6</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Lampros Samartzis et al.</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>We report a unique case of an adverse interaction between the oxazolidinone antibiotic linezolid, the tricyclic antidepressant amitriptyline and the opioid analgesic fentanyl in a 68-year-old woman with advanced ischemic peripheral arterial disease and sepsis, under empirical antibiotic treatment. We also summarize the current relevant literature as identified via PubMed, EMBASE, and PsycINFO as well as reference sections of selected articles.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Case</title><p>Ms. B, a 68-year-old woman, presented at our outpatient clinic with intense lower foot pain and fever since a week. Clinical examination revealed the 3 first phalanges of the left foot painful, cyanotic, and swollen in the absence of palpable pulsus at the ventral and dorsal tibial arteries with concomitant fever (38.5&#x000b0;C) and tachycardia (110&#x02009;bpm). A complete blood count showed elevated total number of white blood cells (21 &#x000d7; 10<sup>9</sup>/L), consisted of 93% from neutrophil granulocytes. She was admitted to our hospital due to sepsis and possible diagnosis of infection of the ischemic left foot. Anamnestic history included advanced peripheral ischemic disease, diabetes mellitus type II, arterial hypertension, and major depression. The patient was receiving treatment with fentanyl transdermal patch 25&#x02009;<italic>&#x003bc;</italic>g/h every 72&#x02009;h since 10 days and amitriptyline 25&#x02009;mg BD for depression. The low dose of amitriptyline 25&#x02009;mg BD was maintained due to its antidepressant [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>] as well as analgesic effects on chronic pain [<xref ref-type="bibr" rid="B3">3</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>] and especially painful diabetic limb [<xref ref-type="bibr" rid="B6">6</xref>&#x02013;<xref ref-type="bibr" rid="B12">12</xref>]. During her stay in the medical ward, she was treated with empirical antibiotics including cloxacillin, 3rd generation beta-lactams, and aminoglycosides with an initial general improvement. However, at the 10th day patient had a new onset of high fever (38.7&#x000b0;C) and linezolid 600&#x02009;mg every 12 hours was added to the treatment regimen and cloxacillin was stopped. Within the first 24 hours of antibiotic change treatment, the patient had a rapid clinical deterioration manifesting symptomatology of restlessness, diaphoresis, tremor, shivering, myoclonus, and high fever (40&#x000b0;C), as well as gradual mental status disorders with disorientation, confusion, and coma. The patient was intubated due to severe respiratory difficulties according to the criteria of our clinic, and transferred to the intensive care unit. Brain computerized tomography and lumbar puncture (LP) for the exclusion of central neural system (CNS) infection were unremarkable. The constellation of the above neurological and mental state features in the presence of serotonergic medication [<xref ref-type="bibr" rid="B13">13</xref>&#x02013;<xref ref-type="bibr" rid="B15">15</xref>] and the abstinence of other CNS pathology leads to the diagnosis of serotonin syndrome according to the diagnostic criteria of Hunter [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>] and Sternbach [<xref ref-type="bibr" rid="B14">14</xref>]. The first signs of improvement appeared a few hours after the interruption of linezolid and amitriptyline. Withdrawal of sedation and ventilator weaning took place 48 hours later. The patient gradually regained her consciousness and orientation to person, location, and time, as expected in the opposite order in which she lost orientation in the beginning of the confusion state [<xref ref-type="bibr" rid="B18">18</xref>]. </p><p>Amitriptyline is a tricyclic antidepressant (TCA), a drug category that is believed to act through boosting of serotonin and norepinephrine neurotransmission via blockade of serotonin and norepinephrine reuptake pumps [<xref ref-type="bibr" rid="B19">19</xref>], as well as via desensitizing both 5-HT<sub>1A</sub> and beta-adrenergic receptors. Tertiary amineTCAs, such asamitriptyline, imipramine, and clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline or desipramine, therefore theoretically more prone to be involved in the development of serotonin syndrome.</p><p>Fentanyl is an synthetic opioid analgesic, which is characterised by high lipid solubility and therefore it easily penetrates the central nervous system (CNS), where it acts through binding to <italic>&#x003bc;</italic>-opioid receptors (mu receptors) resulting in inhibition of pain neurotransmission [<xref ref-type="bibr" rid="B20">20</xref>&#x02013;<xref ref-type="bibr" rid="B22">22</xref>]. Fentanyl belongs to the phenylpiperidine subcategory of opioid substances, as do methadone, pethidine (meperidine), tramadol, propoxyphene, and dextromethorphan. Phenylpiperidine opioids are considered to have mild serotonin-reuptake inhibition (SRI) properties and therefore a higher possibility, for involvement in serotonin syndrome development [<xref ref-type="bibr" rid="B23">23</xref>]. The nonphenylpiperidine opioids, such as buprenorphine, codeine, morphine, and oxycodone, were not reported to show SRI properties [<xref ref-type="bibr" rid="B24">24</xref>]. Interestingly, there is a report of paradoxical reaction regarding fentanyl use in the treatment of serotonin syndrome [<xref ref-type="bibr" rid="B25">25</xref>], which had been induced by coadministration of the selective serotonin reuptake inhibitor (SSRI) fluoxetine and the reversible inhibitor of monoamine oxidase A (MAO-A) moclobemide. </p><p>Linezolid is an oxazolidinone category antibiotic that is believed to act through early inhibition of protein synthesis via binding to the 23S portion of the 50S ribosomal bacterial rRNA subunit [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>] inducing conformational structural changes and preventing tRNA to enter and functionally bind to the ribosome [<xref ref-type="bibr" rid="B28">28</xref>] therefore inhibiting mRNA translation. Linezolid is a totally synthetic compound that was initially synthesized as a reversible MAO inhibitor class antidepressant [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>Serotonin syndrome usually consisted of a constellation of neurological and mental state symptoms and commonly diagnosed according to the widely accepted criteria of Sternbach and/or Hunter [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B30">30</xref>], as summarised in <xref ref-type="table" rid="tab1">Table 1</xref>. Symptoms usually improve with the withdrawal of the predisposing drug agents plus supportive care, as there is no specific evidence-based treatment of the syndrome [<xref ref-type="bibr" rid="B31">31</xref>]. Cyproheptadine is a H<sub>1</sub> histamine receptor antagonist as well as a nonspecific serotonin receptor antagonist [<xref ref-type="bibr" rid="B32">32</xref>] which may have a role in serotonin syndrome treatment in a usual dose of 8&#x02009;mg via the nasogastric tube.</p><p>The development of the serotonin syndrome has been reported as an interaction of linezolid plus almost every category of antidepressant medication. Interactions have been found with the selective serotonin reuptake inhibitors (SSRIs) as citalopram [<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B33">33</xref>&#x02013;<xref ref-type="bibr" rid="B39">39</xref>], escitalopram [<xref ref-type="bibr" rid="B34">34</xref>], paroxetine [<xref ref-type="bibr" rid="B40">40</xref>], fluoxetine [<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>], sertraline [<xref ref-type="bibr" rid="B43">43</xref>&#x02013;<xref ref-type="bibr" rid="B45">45</xref>], with tryptophan, a precursor of serotonin [<xref ref-type="bibr" rid="B46">46</xref>], with noradrenaline and specific serotonergic agents (NaSSA) as mirtazapine [<xref ref-type="bibr" rid="B29">29</xref>], with serotonin 2 antagonist/reuptake inhibitor (SARI) as trazodone [<xref ref-type="bibr" rid="B36">36</xref>], the azapirone category anxiolytic buspirone that is a serotonin 1A partial agonist and serotonin stabilizer [<xref ref-type="bibr" rid="B47">47</xref>], the dual serotonin and noradrenaline reuptake inhibitors (SNRIs) as the antidepressants venlafaxine [<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B51">51</xref>] and duloxetine [<xref ref-type="bibr" rid="B52">52</xref>], and the tricyclic antidepressant (TCA) imipramine [<xref ref-type="bibr" rid="B49">49</xref>]. Although amitriptyline [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B53">53</xref>&#x02013;<xref ref-type="bibr" rid="B56">56</xref>] and fentanyl [<xref ref-type="bibr" rid="B57">57</xref>&#x02013;<xref ref-type="bibr" rid="B64">64</xref>] have been both involved in serotonin syndrome, no case has been reported involving their combination. </p><p>To the knowledge of the authors, this is the first case of serotonin syndrome reported in a patient receiving this common three-drug combination.</p><p>Fentanyl is primarily metabolized via CYP-P450-3A4 isoenzyme system by oxidative dealkylation to the main metabolite norfentanyl which is inactive [<xref ref-type="bibr" rid="B65">65</xref>].</p><p>Amitriptyline is metabolised via CYP-P450-1A2 isoenzyme by demethylation to form the active metabolite nortriptyline [<xref ref-type="bibr" rid="B66">66</xref>] and via CYP-P450-2D6 by hydroxylation to form inactive metabolites [<xref ref-type="bibr" rid="B19">19</xref>], but there is also data showing that demethylation via CYP-P450-3A4 plays an important role in its metabolism [<xref ref-type="bibr" rid="B67">67</xref>&#x02013;<xref ref-type="bibr" rid="B69">69</xref>]. Therefore a pharmacokinetic interaction between fentanyl and amitriptyline could not be excluded. Nevertheless, in our case, coadministration of amitriptyline and fentanyl did not reveal any symptomatic interaction, as the serotonin syndrome was induced only after the addition of linezolid to the treatment regimen. </p><p>Linezolide is metabolised via oxidation procedure in a way independent of cytochrome P450 (CYP-450); consequently there is no possible pharmacokinetic mechanism of interaction between linezolide and other medication metabolized through CYP450 pathways [<xref ref-type="bibr" rid="B27">27</xref>].</p><p>Also, the serotonin syndrome pathophysiological mechanism does not include idiosyncratic, neither idiopathic nor pharmacokinetic drug reactions, but it is considered to be a predictable and preventable pharmacodynamic consequence of the excess of serotonergic agonism in CNS and peripheral serotonergic receptors [<xref ref-type="bibr" rid="B17">17</xref>].</p><p>We suggest that physicians avoid use of linezolid in patients receiving combination of amitriptyline and fentanyl due to possible serotonin syndrome induction.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guaiana</surname><given-names>G</given-names></name><name><surname>Barbui</surname><given-names>C</given-names></name><name><surname>Hotopf</surname><given-names>M</given-names></name></person-group><article-title>Amitriptyline for depression</article-title><source><italic>Cochrane Database of Systematic Reviews</italic></source><year>2007</year><issue>3</issue><pub-id pub-id-type="other">2-s2.0-35348922807</pub-id><pub-id pub-id-type="publisher-id">CD004186</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbui</surname><given-names>C</given-names></name><name><surname>Hotopf</surname><given-names>M</given-names></name></person-group><article-title>Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials</article-title><source><italic>British Journal of Psychiatry</italic></source><year>2001</year><volume>178</volume><fpage>129</fpage><lpage>144</lpage><pub-id pub-id-type="other">2-s2.0-0035137253</pub-id><pub-id pub-id-type="pmid">11157426</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>ME</given-names></name></person-group><article-title>Antidepressants as analgesics: a review of randomized controlled trials</article-title><source><italic>Journal of Psychiatry and Neuroscience</italic></source><year>2001</year><volume>26</volume><issue>1</issue><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="other">2-s2.0-0035120656</pub-id><pub-id pub-id-type="pmid">11212591</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawynok</surname><given-names>J</given-names></name><name><surname>Esser</surname><given-names>MJ</given-names></name><name><surname>Reid</surname><given-names>AR</given-names></name></person-group><article-title>Antidepressants as analgesics: an overview of central and peripheral mechanisms of action</article-title><source><italic>Journal of Psychiatry and Neuroscience</italic></source><year>2001</year><volume>26</volume><issue>1</issue><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="other">2-s2.0-0035120761</pub-id><pub-id pub-id-type="pmid">11212590</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botney</surname><given-names>M</given-names></name><name><surname>Fields</surname><given-names>JL</given-names></name></person-group><article-title>Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system</article-title><source><italic>Annals of Neurology</italic></source><year>1983</year><volume>13</volume><issue>2</issue><fpage>160</fpage><lpage>164</lpage><pub-id pub-id-type="other">2-s2.0-0020680680</pub-id><pub-id pub-id-type="pmid">6219612</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryson</surname><given-names>HM</given-names></name><name><surname>Wilde</surname><given-names>MI</given-names></name></person-group><article-title>Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states</article-title><source><italic>Drugs and Aging</italic></source><year>1996</year><volume>8</volume><issue>6</issue><fpage>459</fpage><lpage>476</lpage><pub-id pub-id-type="other">2-s2.0-0029897246</pub-id><pub-id pub-id-type="pmid">8736630</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bril</surname><given-names>V</given-names></name></person-group><article-title>Treatments for diabetic neuropathy</article-title><source><italic>Journal of the Peripheral Nervous System</italic></source><year>2012</year><volume>17</volume><issue>supplement 2</issue><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">22548619</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bril</surname><given-names>V</given-names></name><name><surname>England</surname><given-names>J</given-names></name><name><surname>Franklin</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Evidence-based guideline: treatment of painful diabetic neuropathy. Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation</article-title><source><italic>Physical Medicine and Rehabilitation</italic></source><year>2011</year><volume>3</volume><issue>4</issue><fpage>345e1</fpage><lpage>352e21</lpage><pub-id pub-id-type="other">2-s2.0-79954564711</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cayley</surname><given-names>WE</given-names><suffix>Jr.</suffix></name></person-group><article-title>Antidepressants for the treatment of neuropathic pain</article-title><source><italic>American Family Physician</italic></source><year>2006</year><volume>73</volume><issue>11</issue><fpage>1933</fpage><lpage>1936</lpage><pub-id pub-id-type="other">2-s2.0-33744948942</pub-id><pub-id pub-id-type="pmid">16770921</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joss</surname><given-names>JD</given-names></name></person-group><article-title>Tricyclic antidepressant use in diabetic neuropathy</article-title><source><italic>Annals of Pharmacotherapy</italic></source><year>1999</year><volume>33</volume><issue>9</issue><fpage>996</fpage><lpage>1000</lpage><pub-id pub-id-type="other">2-s2.0-0032863692</pub-id><pub-id pub-id-type="pmid">10492505</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopsky</surname><given-names>DJ</given-names></name><name><surname>Keppel Hesselink</surname><given-names>JM</given-names></name></person-group><article-title>High doses of topical amitriptyline in nuropathic pain: two cases and literature review</article-title><source><italic>Pain Pract</italic></source><year>2012</year><volume>12</volume><fpage>148</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">21676162</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Max</surname><given-names>MB</given-names></name><name><surname>Culnane</surname><given-names>M</given-names></name><name><surname>Schafer</surname><given-names>SC</given-names></name></person-group><article-title>Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood</article-title><source><italic>Neurology</italic></source><year>1987</year><volume>37</volume><issue>4</issue><fpage>589</fpage><lpage>596</lpage><pub-id pub-id-type="other">2-s2.0-0023155057</pub-id><pub-id pub-id-type="pmid">2436092</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>D</given-names></name><name><surname>Paton</surname><given-names>C</given-names></name><name><surname>Kapur</surname><given-names>S</given-names></name></person-group><source><italic>The Maudsley Prescribing Guidelines in Psychiatry</italic></source><year>2012</year><publisher-loc>Cornwall, UK</publisher-loc><publisher-name>Wiley</publisher-name></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sternbach</surname><given-names>H</given-names></name></person-group><article-title>The serotonin syndrome</article-title><source><italic>American Journal of Psychiatry</italic></source><year>1991</year><volume>148</volume><issue>6</issue><fpage>705</fpage><lpage>713</lpage><pub-id pub-id-type="other">2-s2.0-0025869797</pub-id><pub-id pub-id-type="pmid">2035713</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shameen</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name></person-group><article-title>Serotonin syndrome</article-title><source><italic>Psychiatric Bulletin</italic></source><year>1999</year><volume>23</volume><fpage>742</fpage><lpage>747</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunkley</surname><given-names>EJC</given-names></name><name><surname>Isbister</surname><given-names>GK</given-names></name><name><surname>Sibbritt</surname><given-names>D</given-names></name><name><surname>Dawson</surname><given-names>AH</given-names></name><name><surname>Whyte</surname><given-names>IM</given-names></name></person-group><article-title>The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity</article-title><source><italic>QJM</italic></source><year>2003</year><volume>96</volume><issue>9</issue><fpage>635</fpage><lpage>642</lpage><pub-id pub-id-type="other">2-s2.0-0042377403</pub-id><pub-id pub-id-type="pmid">12925718</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>EW</given-names></name><name><surname>Shannon</surname><given-names>M</given-names></name></person-group><article-title>Current concepts: the serotonin syndrome</article-title><source><italic>New England Journal of Medicine</italic></source><year>2005</year><volume>352</volume><issue>11</issue><fpage>1112</fpage><lpage>1120</lpage><pub-id pub-id-type="other">2-s2.0-15044361698</pub-id><pub-id pub-id-type="pmid">15784664</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Casey</surname><given-names>PR</given-names></name><name><surname>Kelly</surname><given-names>B</given-names></name></person-group><source><italic>Fish&#x02019;s Clinical Psychopathology: Signs and Symptoms in Psychiatry</italic></source><year>2007</year><publisher-loc>Glasgow, UK</publisher-loc><publisher-name>Royal College of Psychiatrists</publisher-name></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>SM</given-names></name></person-group><source><italic>Essential Psychopharmacology, Neuroscientific Basis and Practical Applications</italic></source><year>2008</year><edition>3rd edition</edition><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Cambridge University Press</publisher-name></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>S</given-names></name><name><surname>Narita</surname><given-names>M</given-names></name><name><surname>Ozeki</surname><given-names>A</given-names></name><etal/></person-group><article-title>Difference in tolerance to anti-hyperalgesic effect and its molecular mechanisms between chronic treatment with morphine, fentanyl and oxycodone in a chronic pain-like state</article-title><source><italic>Nihon Shinkei Seishin Yakurigaku Zasshi</italic></source><year>2008</year><volume>28</volume><issue>5-6</issue><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="other">2-s2.0-58049109880</pub-id><pub-id pub-id-type="pmid">19108502</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muijsers</surname><given-names>RBR</given-names></name><name><surname>Wagstaff</surname><given-names>AJ</given-names></name></person-group><article-title>Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control</article-title><source><italic>Drugs</italic></source><year>2001</year><volume>61</volume><issue>15</issue><fpage>2289</fpage><lpage>2307</lpage><pub-id pub-id-type="other">2-s2.0-0035695653</pub-id><pub-id pub-id-type="pmid">11772140</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>G</given-names></name><name><surname>Ferguson</surname><given-names>DM</given-names></name></person-group><article-title>Conformational landscape of selective <italic>&#x003bc;</italic>-opioid agonists in gas phase and in aqueous solution: the fentanyl series</article-title><source><italic>Drug Design and Discovery</italic></source><year>2000</year><volume>17</volume><issue>1</issue><fpage>55</fpage><lpage>67</lpage><pub-id pub-id-type="other">2-s2.0-0034088315</pub-id><pub-id pub-id-type="pmid">10928449</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Codd</surname><given-names>EE</given-names></name><name><surname>Shank</surname><given-names>RP</given-names></name><name><surname>Schupsky</surname><given-names>JJ</given-names></name><name><surname>Raffa</surname><given-names>RB</given-names></name></person-group><article-title>Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception</article-title><source><italic>Journal of Pharmacology and Experimental Therapeutics</italic></source><year>1995</year><volume>274</volume><issue>3</issue><fpage>1263</fpage><lpage>1270</lpage><pub-id pub-id-type="other">2-s2.0-0029048267</pub-id><pub-id pub-id-type="pmid">7562497</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillman</surname><given-names>PK</given-names></name></person-group><article-title>Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity</article-title><source><italic>British Journal of Anaesthesia</italic></source><year>2005</year><volume>95</volume><issue>4</issue><fpage>434</fpage><lpage>441</lpage><pub-id pub-id-type="other">2-s2.0-26444511151</pub-id><pub-id pub-id-type="pmid">16051647</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambost</surname><given-names>M</given-names></name><name><surname>Liron</surname><given-names>L</given-names></name><name><surname>Peillon</surname><given-names>D</given-names></name><name><surname>Combe</surname><given-names>C</given-names></name></person-group><article-title>Serotonin syndrome during fluoxetine intoxication in a patient using moclobemide</article-title><source><italic>Canadian Journal of Anesthesia</italic></source><year>2000</year><volume>47</volume><issue>3</issue><fpage>246</fpage><lpage>250</lpage><pub-id pub-id-type="other">2-s2.0-0033624706</pub-id><pub-id pub-id-type="pmid">10730736</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paladino</surname><given-names>JA</given-names></name></person-group><article-title>Linezolid: an oxazolidinone antimicrobial agent</article-title><source><italic>American Journal of Health-System Pharmacy</italic></source><year>2002</year><volume>59</volume><issue>24</issue><fpage>2413</fpage><lpage>2425</lpage><pub-id pub-id-type="other">2-s2.0-0037115316</pub-id><pub-id pub-id-type="pmid">12503340</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>HB</given-names></name><name><surname>Kirschenbaum</surname><given-names>HL</given-names></name><name><surname>Ojofeitimi</surname><given-names>BO</given-names></name></person-group><article-title>Linezolid: an oxazolidinone antimicrobial agent</article-title><source><italic>Clinical Therapeutics</italic></source><year>2001</year><volume>23</volume><issue>3</issue><fpage>356</fpage><lpage>391</lpage><pub-id pub-id-type="other">2-s2.0-0035293206</pub-id><pub-id pub-id-type="pmid">11318073</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>DN</given-names></name><name><surname>Schluenzen</surname><given-names>F</given-names></name><name><surname>Harms</surname><given-names>JM</given-names></name><name><surname>Starosta</surname><given-names>AL</given-names></name><name><surname>Connell</surname><given-names>SR</given-names></name><name><surname>Fucini</surname><given-names>P</given-names></name></person-group><article-title>The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2008</year><volume>105</volume><issue>36</issue><fpage>13339</fpage><lpage>13344</lpage><pub-id pub-id-type="other">2-s2.0-51649117099</pub-id><pub-id pub-id-type="pmid">18757750</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBellis</surname><given-names>RJ</given-names></name><name><surname>Schaefer</surname><given-names>OP</given-names></name><name><surname>Liquori</surname><given-names>M</given-names></name><name><surname>Volturo</surname><given-names>GA</given-names></name></person-group><article-title>Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient</article-title><source><italic>Journal of Intensive Care Medicine</italic></source><year>2005</year><volume>20</volume><issue>6</issue><fpage>351</fpage><lpage>353</lpage><pub-id pub-id-type="other">2-s2.0-33644845111</pub-id><pub-id pub-id-type="pmid">16280409</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>JJ</given-names></name><name><surname>Wilson</surname><given-names>JW</given-names></name><name><surname>Estes</surname><given-names>LL</given-names></name></person-group><article-title>Linezolid and serotonergic drug interactions: a retrospective survey</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2006</year><volume>43</volume><issue>2</issue><fpage>180</fpage><lpage>187</lpage><pub-id pub-id-type="other">2-s2.0-33745728381</pub-id><pub-id pub-id-type="pmid">16779744</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>PJ</given-names></name><name><surname>Wilborn</surname><given-names>CA</given-names></name></person-group><article-title>Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management</article-title><source><italic>Annals of Clinical Psychiatry</italic></source><year>2012</year><volume>24</volume><issue>2</issue><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">22563571</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graudins</surname><given-names>A</given-names></name><name><surname>Stearman</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>B</given-names></name><name><surname>Kulig</surname><given-names>K</given-names></name></person-group><article-title>Treatment of the serotonin syndrome with cyproheptadine</article-title><source><italic>Journal of Emergency Medicine</italic></source><year>1998</year><volume>16</volume><issue>4</issue><fpage>615</fpage><lpage>619</lpage><pub-id pub-id-type="other">2-s2.0-0032126928</pub-id><pub-id pub-id-type="pmid">9696181</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClean</surname><given-names>M</given-names></name><name><surname>Walsh</surname><given-names>JC</given-names></name><name><surname>Condon</surname><given-names>F</given-names></name></person-group><article-title>Serotonin syndrome in an orthopaedic patient secondary to linezolid therapy for MRSA infection</article-title><source><italic>Irish Journal of Medical Science</italic></source><year>2011</year><volume>180</volume><issue>1</issue><fpage>285</fpage><lpage>286</lpage><pub-id pub-id-type="other">2-s2.0-79954437837</pub-id><pub-id pub-id-type="pmid">20886306</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>RA</given-names></name><name><surname>Vandenberg</surname><given-names>AM</given-names></name><name><surname>Canepa</surname><given-names>EA</given-names></name></person-group><article-title>Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases</article-title><source><italic>International Journal of Psychiatry in Medicine</italic></source><year>2008</year><volume>38</volume><issue>1</issue><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="other">2-s2.0-50649105318</pub-id><pub-id pub-id-type="pmid">18624020</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>AC</given-names></name><name><surname>Golightly</surname><given-names>LK</given-names></name><name><surname>Barber</surname><given-names>GR</given-names></name><name><surname>Barron</surname><given-names>MA</given-names></name></person-group><article-title>Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment</article-title><source><italic>Drug Metabolism and Drug Interactions</italic></source><year>2010</year><volume>25</volume><issue>1</issue><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="other">2-s2.0-79951488058</pub-id><pub-id pub-id-type="pmid">21417793</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergeron</surname><given-names>L</given-names></name><name><surname>Boul&#x000e9;</surname><given-names>M</given-names></name><name><surname>Perreault</surname><given-names>S</given-names></name></person-group><article-title>Serotonin toxicity associated with concomitant use of linezolid</article-title><source><italic>Annals of Pharmacotherapy</italic></source><year>2005</year><volume>39</volume><issue>5</issue><fpage>956</fpage><lpage>961</lpage><pub-id pub-id-type="other">2-s2.0-17644383350</pub-id><pub-id pub-id-type="pmid">15827071</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>L</given-names></name><name><surname>Stern</surname><given-names>R</given-names></name><name><surname>Lew</surname><given-names>D</given-names></name><name><surname>Hoffmeyer</surname><given-names>P</given-names></name></person-group><article-title>Serotonin syndrome after concomitant treatment with linezolid and citalopram</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2003</year><volume>36</volume><issue>9</issue><fpage>p. 1197</fpage><pub-id pub-id-type="other">2-s2.0-0038556783</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahir</surname><given-names>N</given-names></name></person-group><article-title>Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram</article-title><source><italic>Journal of the American Medical Directors Association</italic></source><year>2004</year><volume>5</volume><issue>2</issue><fpage>111</fpage><lpage>113</lpage><pub-id pub-id-type="other">2-s2.0-1642408641</pub-id><pub-id pub-id-type="pmid">14984623</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hachem</surname><given-names>RY</given-names></name><name><surname>Hicks</surname><given-names>K</given-names></name><name><surname>Huen</surname><given-names>A</given-names></name><name><surname>Raad</surname><given-names>I</given-names></name></person-group><article-title>Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2003</year><volume>37</volume><issue>1</issue><fpage>e8</fpage><lpage>11</lpage><pub-id pub-id-type="other">2-s2.0-0347276001</pub-id><pub-id pub-id-type="pmid">12830431</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wigen</surname><given-names>CL</given-names></name><name><surname>Goetz</surname><given-names>MB</given-names></name></person-group><article-title>Serotonin syndrome and linezolid</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>2002</year><volume>34</volume><issue>12</issue><fpage>1651</fpage><lpage>1652</lpage><pub-id pub-id-type="other">2-s2.0-0037097653</pub-id><pub-id pub-id-type="pmid">12032904</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>M</given-names></name><name><surname>Morin</surname><given-names>AK</given-names></name></person-group><article-title>Mild serotonin syndrome associated with concurrent linezolid and fluoxetine</article-title><source><italic>American Journal of Health-System Pharmacy</italic></source><year>2007</year><volume>64</volume><issue>1</issue><fpage>59</fpage><lpage>62</lpage><pub-id pub-id-type="other">2-s2.0-33947125982</pub-id><pub-id pub-id-type="pmid">17189581</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>CR</given-names></name><name><surname>Rosenberg</surname><given-names>M</given-names></name><name><surname>Blythe</surname><given-names>V</given-names></name><name><surname>Meyer</surname><given-names>WJ</given-names></name></person-group><article-title>Serotonin syndrome and linezolid</article-title><source><italic>Journal of the American Academy of Child and Adolescent Psychiatry</italic></source><year>2004</year><volume>43</volume><issue>7</issue><fpage>p. 790</fpage><pub-id pub-id-type="other">2-s2.0-3042607958</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavery</surname><given-names>S</given-names></name><name><surname>Ravi</surname><given-names>H</given-names></name><name><surname>McDaniel</surname><given-names>WW</given-names></name><name><surname>Pushkin</surname><given-names>YR</given-names></name></person-group><article-title>Linezolid and serotonin syndrome</article-title><source><italic>Psychosomatics</italic></source><year>2001</year><volume>42</volume><issue>5</issue><fpage>432</fpage><lpage>434</lpage><pub-id pub-id-type="other">2-s2.0-0034766452</pub-id><pub-id pub-id-type="pmid">11739912</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahiner</surname><given-names>V</given-names></name><name><surname>Erden Aki</surname><given-names>SO</given-names></name></person-group><article-title>Serotonin syndrome associated with linezolid use: a case report</article-title><source><italic>T&#x000fc;rk Psikiyatri Dergisi</italic></source><year>2009</year><volume>20</volume><issue>4</issue><fpage>398</fpage><lpage>402</lpage><pub-id pub-id-type="other">2-s2.0-77951632791</pub-id><pub-id pub-id-type="pmid">20013432</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>DB</given-names></name><name><surname>Andrus</surname><given-names>MR</given-names></name><name><surname>Byrd</surname><given-names>DC</given-names></name></person-group><article-title>Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature</article-title><source><italic>Pharmacotherapy</italic></source><year>2006</year><volume>26</volume><issue>2</issue><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="other">2-s2.0-32044443633</pub-id><pub-id pub-id-type="pmid">16466332</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colomar Ferr&#x000e1;</surname><given-names>A</given-names></name><name><surname>Ventayol Bosch</surname><given-names>P</given-names></name><name><surname>Raurich</surname><given-names>JM</given-names></name></person-group><article-title>Serotonin syndrome due to interaction between linezolid, tryptophan, and metoclopramide</article-title><source><italic>Medicina Intensiva</italic></source><year>2009</year><volume>33</volume><issue>7</issue><fpage>360</fpage><lpage>361</lpage><pub-id pub-id-type="other">2-s2.0-70349417695</pub-id><pub-id pub-id-type="pmid">19828401</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>EK</given-names></name><name><surname>Rowe</surname><given-names>AS</given-names></name></person-group><article-title>Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia</article-title><source><italic>International Journal of Clinical Pharmacology and Therapeutics</italic></source><year>2012</year><volume>37</volume><issue>5</issue><fpage>610</fpage><lpage>613</lpage></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>LW</given-names></name><name><surname>Randhawa</surname><given-names>KS</given-names></name><name><surname>Carpenter</surname><given-names>EC</given-names></name></person-group><article-title>Serotonin toxicity as a consequence of linezolid use in revision hip arthroplasty</article-title><source><italic>Orthopedics</italic></source><year>2008</year><volume>31</volume><issue>11</issue><fpage>p. 1140</fpage><pub-id pub-id-type="other">2-s2.0-65349130712</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DG</given-names></name><name><surname>Lovell</surname><given-names>EO</given-names></name></person-group><article-title>Antibiotic-induced serotonin syndrome</article-title><source><italic>Journal of Emergency Medicine</italic></source><year>2011</year><volume>40</volume><issue>1</issue><fpage>25</fpage><lpage>27</lpage><pub-id pub-id-type="other">2-s2.0-78651107682</pub-id><pub-id pub-id-type="pmid">18455905</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packer</surname><given-names>S</given-names></name><name><surname>Berman</surname><given-names>SA</given-names></name></person-group><article-title>Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid</article-title><source><italic>American Journal of Psychiatry</italic></source><year>2007</year><volume>164</volume><issue>2</issue><fpage>346</fpage><lpage>347</lpage><pub-id pub-id-type="other">2-s2.0-33847257851</pub-id><pub-id pub-id-type="pmid">17267801</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>SL</given-names></name><name><surname>Athan</surname><given-names>E</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>D</given-names></name></person-group><article-title>Serotonin syndrome due to co-administration of linezolid and venlafaxine</article-title><source><italic>Journal of Antimicrobial Chemotherapy</italic></source><year>2004</year><volume>54</volume><issue>1</issue><fpage>289</fpage><lpage>290</lpage><pub-id pub-id-type="other">2-s2.0-3543060108</pub-id><pub-id pub-id-type="pmid">15140859</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strouse</surname><given-names>TB</given-names></name><name><surname>Kerrihard</surname><given-names>TN</given-names></name><name><surname>Forscher</surname><given-names>CA</given-names></name><name><surname>Zakowski</surname><given-names>P</given-names></name></person-group><article-title>Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine</article-title><source><italic>Journal of Clinical Psychopharmacology</italic></source><year>2006</year><volume>26</volume><issue>6</issue><fpage>681</fpage><lpage>683</lpage><pub-id pub-id-type="other">2-s2.0-33751092818</pub-id><pub-id pub-id-type="pmid">17110838</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodner</surname><given-names>RA</given-names></name><name><surname>Lynch</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>L</given-names></name><name><surname>Kahn</surname><given-names>D</given-names></name></person-group><article-title>Serotonin syndrome</article-title><source><italic>Neurology</italic></source><year>1995</year><volume>45</volume><issue>2</issue><fpage>219</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">7854515</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>R</given-names></name><name><surname>Baldwin</surname><given-names>D</given-names></name></person-group><article-title>Selective serotonin reuptake inhibitor-induced serotonin syndrome: review</article-title><source><italic>Journal of Clinical Psychopharmacology</italic></source><year>1997</year><volume>17</volume><issue>3</issue><fpage>208</fpage><lpage>221</lpage><pub-id pub-id-type="other">2-s2.0-0030984995</pub-id><pub-id pub-id-type="pmid">9169967</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nisijima</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Ishiguro</surname><given-names>T</given-names></name></person-group><article-title>A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium</article-title><source><italic>International Clinical Psychopharmacology</italic></source><year>1996</year><volume>11</volume><issue>4</issue><fpage>289</fpage><lpage>290</lpage><pub-id pub-id-type="other">2-s2.0-0030480359</pub-id><pub-id pub-id-type="pmid">9031998</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>NK</given-names></name></person-group><article-title>Venlafaxine-induced serotonin syndrome with relapse following amitriptyline</article-title><source><italic>Postgraduate Medical Journal</italic></source><year>2000</year><volume>76</volume><issue>894</issue><fpage>254</fpage><lpage>256</lpage><pub-id pub-id-type="other">2-s2.0-0034103871</pub-id><pub-id pub-id-type="pmid">10727586</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ailawadhi</surname><given-names>S</given-names></name><name><surname>Sung</surname><given-names>KW</given-names></name><name><surname>Carlson</surname><given-names>LA</given-names></name><name><surname>Baer</surname><given-names>MR</given-names></name></person-group><article-title>Serotonin syndrome caused by interaction between citalopram and fentanyl</article-title><source><italic>Journal of Clinical Pharmacy and Therapeutics</italic></source><year>2007</year><volume>32</volume><issue>2</issue><fpage>199</fpage><lpage>202</lpage><pub-id pub-id-type="other">2-s2.0-33947412320</pub-id><pub-id pub-id-type="pmid">17381671</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhatib</surname><given-names>AA</given-names></name><name><surname>Peterson</surname><given-names>KA</given-names></name><name><surname>Tuteja</surname><given-names>AK</given-names></name></person-group><article-title>Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy</article-title><source><italic>Digestive Diseases and Sciences</italic></source><year>2010</year><volume>55</volume><issue>1</issue><fpage>215</fpage><lpage>216</lpage><pub-id pub-id-type="other">2-s2.0-74049139923</pub-id><pub-id pub-id-type="pmid">19165596</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giese</surname><given-names>SY</given-names></name><name><surname>Neborsky</surname><given-names>R</given-names></name></person-group><article-title>Serotonin syndrome: potential consequences of Meridia combined with Demerol or Fentanyl</article-title><source><italic>Plastic and Reconstructive Surgery</italic></source><year>2001</year><volume>107</volume><issue>1</issue><fpage>293</fpage><lpage>294</lpage><pub-id pub-id-type="other">2-s2.0-0035171195</pub-id><pub-id pub-id-type="pmid">11176649</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gollapudy</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Dhamee</surname><given-names>MS</given-names></name></person-group><article-title>A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion</article-title><source><italic>Journal of Clinical Anesthesia</italic></source><year>2012</year><volume>24</volume><issue>3</issue><fpage>251</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">22537574</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirschner</surname><given-names>R</given-names></name><name><surname>Donovan</surname><given-names>JW</given-names></name></person-group><article-title>Serotonin syndrome precipitated by fentanyl during procedural sedation</article-title><source><italic>Journal of Emergency Medicine</italic></source><year>2010</year><volume>38</volume><issue>4</issue><fpage>477</fpage><lpage>480</lpage><pub-id pub-id-type="other">2-s2.0-77951667773</pub-id><pub-id pub-id-type="pmid">18757161</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozkardesler</surname><given-names>S</given-names></name><name><surname>Gurpinar</surname><given-names>T</given-names></name><name><surname>Akan</surname><given-names>M</given-names></name><etal/></person-group><article-title>A possible perianesthetic serotonin syndrome related to intrathecal fentanyl</article-title><source><italic>Journal of Clinical Anesthesia</italic></source><year>2008</year><volume>20</volume><issue>2</issue><fpage>143</fpage><lpage>145</lpage><pub-id pub-id-type="other">2-s2.0-41849116718</pub-id><pub-id pub-id-type="pmid">18410872</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reich</surname><given-names>M</given-names></name><name><surname>Lefebvre-Kuntz</surname><given-names>D</given-names></name></person-group><article-title>Serotoninergic antidepressants and opiate analgesics: a sometimes-painful association. A case report</article-title><source><italic>Encephale</italic></source><year>2010</year><volume>36</volume><issue>supplement 2</issue><fpage>D119</fpage><lpage>D123</lpage><pub-id pub-id-type="other">2-s2.0-77953022648</pub-id><pub-id pub-id-type="pmid">20513454</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastogi</surname><given-names>R</given-names></name><name><surname>Swarm</surname><given-names>RA</given-names></name><name><surname>Patel</surname><given-names>TA</given-names></name></person-group><article-title>Case scenario: opioid association with serotonin syndrome: implications to the practitioners</article-title><source><italic>Anesthesiology</italic></source><year>2011</year><volume>115</volume><issue>6</issue><fpage>1291</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">22037635</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feierman</surname><given-names>DE</given-names></name><name><surname>Lasker</surname><given-names>JM</given-names></name></person-group><article-title>Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes: role of CYP3A4</article-title><source><italic>Drug Metabolism and Disposition</italic></source><year>1996</year><volume>24</volume><issue>9</issue><fpage>932</fpage><lpage>939</lpage><pub-id pub-id-type="other">2-s2.0-0029813838</pub-id><pub-id pub-id-type="pmid">8886601</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>SM</given-names></name></person-group><source><italic>Essential Psychopharmacology: the Prescriber&#x02019;s Guide</italic></source><year>2009</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Cambridge University Press</publisher-name></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatakrishnan</surname><given-names>K</given-names></name><name><surname>Greenblatt</surname><given-names>DJ</given-names></name><name><surname>Von Moltke</surname><given-names>LL</given-names></name><name><surname>Schmider</surname><given-names>J</given-names></name><name><surname>Harmatz</surname><given-names>JS</given-names></name><name><surname>Shader</surname><given-names>RI</given-names></name></person-group><article-title>Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4</article-title><source><italic>Journal of Clinical Pharmacology</italic></source><year>1998</year><volume>38</volume><issue>2</issue><fpage>112</fpage><lpage>121</lpage><pub-id pub-id-type="other">2-s2.0-0031908744</pub-id><pub-id pub-id-type="pmid">9549641</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>OV</given-names></name><name><surname>Linnet</surname><given-names>K</given-names></name></person-group><article-title>Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes</article-title><source><italic>Pharmacology</italic></source><year>1997</year><volume>55</volume><issue>5</issue><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="other">2-s2.0-0030735733</pub-id><pub-id pub-id-type="pmid">9399333</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghahramani</surname><given-names>P</given-names></name><name><surname>Ellis</surname><given-names>SW</given-names></name><name><surname>Lennard</surname><given-names>MS</given-names></name><name><surname>Ramsay</surname><given-names>LE</given-names></name><name><surname>Tucker</surname><given-names>GT</given-names></name></person-group><article-title>Cytochromes P450 mediating the N-demethylation of amitriptyline</article-title><source><italic>British Journal of Clinical Pharmacology</italic></source><year>1997</year><volume>43</volume><issue>2</issue><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="other">2-s2.0-0031058342</pub-id><pub-id pub-id-type="pmid">9131945</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Widely accepted diagnostic criteria for serotonin syndrome. </p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">Criteria of Hunter, 2003 [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>].</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Presence of a serotonergic agent and 1 of 5</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;(1) Spontaneous clonus</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;(2) Inducible clonus and agitation or diaphoresis</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;(3) Ocular clonus and agitation or diaphoresis</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;(4) Tremor and hyperreflexia, or</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;(5) Hypertonia and temperature &#x0003e;38&#x000b0;C and ocular clonus or <break/>&#x02003;&#x02003;inducible clonus</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Criteria of Sternbach, 1991 [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B30">30</xref>].</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Presence of all of the following</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">(a) Recent addition or increase in a known serotonergic agent</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">(b) Absence of other possible aetiologies (infection, substance <break/>&#x02003;&#x02009;&#x02009;abuse, substance withdrawal, etc.)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">(c) No recent addition or increase of a neuroleptic agent</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">(d) At least 3 of the following 10</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (1) Mental status changes (confusion, hypomania)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (2) Agitation</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (3) Myoclonus</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (4) Hyperreflexia</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (5) Diaphoresis</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (6) Shivering</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (7) Tremor</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (8) Diarrhoea</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (9) Incoordination</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003; (10) Fever</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr></tbody></table></table-wrap></floats-group></article>